Endo and Penwest settle litigation with Actavis

Published: 25-Feb-2009

Endo Pharmaceuticals, a specialty pharmaceutical company, and Penwest Pharmaceuticals, a drug development company, have settled litigation with Actavis South Atlantic, a generic pharmaceutical company, regarding the production and sale of generic formulations of Opana extended release tablets CII.

Endo and Penwest have agreed to dismiss their suit with prejudice and Actavis has agreed to dismiss its counterclaims with prejudice.

Under the terms of the settlement, Endo and Penwest have agreed to grant Actavis a license and a covenant not to sue to the patents in suit to sell a generic of Opana extended release on or after July 15, 2011, and earlier under certain circumstances.

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include Lidoderm, Percocet and Percodan, Frova, Opana, and Voltaren gel. The company markets it’s pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care.

Penwest is a drug development company focused on identifying, developing and commercializing products that address unmet medical needs, primarily for disorders of the nervous system. Penwest is currently applying its drug development and drug delivery expertise to the development of products that are in various stages of development, and that it intends to commercialize independently or through third party alliances.

Tell your friend about this article